Coagulation factor VIII — Drug Target

All drugs that target Coagulation factor VIII — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Drug classes

Recombinant protein therapy · Recombinant coagulation factor VIII · Recombinant clotting factor · Coagulation factor replacement therapy · Long-acting recombinant factor VIII (PEGylated) · Recombinant coagulation factor VIII (pegylated)

Marketed (8)

• Xyntha · Pfizer · Recombinant protein therapy · Rare Disease
• OBIZUR · Baxalta now part of Shire · Recombinant coagulation factor VIII · Hematology
  OBIZUR is a recombinant human Factor VIII that replaces deficient or dysfunctional Factor VIII to restore blood clotting ability in patients with hemophilia A.
• Kogenate (BAY14-2222) · Bayer · Recombinant coagulation factor VIII · Hematology
  Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Kogenate (BAY 14-2222) · Bayer · Recombinant coagulation factor VIII · Hematology
  Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Recombinant Factor VIII (rAHF) · Baxalta now part of Shire · Recombinant clotting factor · Hematology
  Recombinant Factor VIII replaces the missing or deficient clotting factor VIII protein to restore the intrinsic coagulation pathway and enable normal blood clot formation.
• Moroctocog alfa (AF-CC) · Pfizer · Recombinant coagulation factor VIII · Hematology
  Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Recombinant Human Coagulation FVIII · Sinocelltech Ltd. · Coagulation factor replacement therapy · Hematology
  Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.
• Intravenous infusions of Xyntha · Pfizer · Recombinant coagulation factor VIII · Hematology
  Xyntha is a recombinant coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.

Phase 3 pipeline (3)

• BAY94-9027 · Bayer · Long-acting recombinant factor VIII (PEGylated) · Hematology
  BAY94-9027 is a long-acting factor VIII replacement therapy that extends the half-life of clotting factor VIII through PEGylation, reducing dosing frequency in hemophilia A patients.
• BAX 326 · Baxalta now part of Shire · Recombinant coagulation factor VIII · Hematology
  BAX 326 is a recombinant human coagulation factor VIII designed to treat hemophilia A by replacing deficient or dysfunctional factor VIII.
• Turoctocog alfa pegol (N8-GP) · Novo Nordisk A/S · Recombinant coagulation factor VIII (pegylated) · Hematology
  Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients.